Viluksela M, Stahl B U, Birnbaum L S, Schramm K W, Kettrup A, Rozman K K
Department of Pharmacology, Toxicology, and Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, 66160-7417, USA.
Toxicol Appl Pharmacol. 1998 Jul;151(1):57-69. doi: 10.1006/taap.1998.8384.
Groups of 20 male and 20 female rats were administered five different doses of a mixture of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), 1,2,3,7,8-pentaCDD (PCDD), 1,2,3,4,7,8-hexaCDD (HxCDD), and 1,2,3,4,6,7,8-heptaCDD (HpCDD). Doses were selected based on relative potency factors derived from acute toxicity data and a previous subchronic study with HpCDD. The mixture was constituted such that each of the congeners contributed one fourth to total toxic equivalency. Total doses were divided into four daily loading doses and six biweekly maintenance doses. The highest total dose for males was 17.5 microg/kg of TCDD, 87.5 microg/kg of PCDD, 350 microg/kg of HxCDD, and 2500 microg/kg of HpCDD. Positive controls were administered PCDD (350 microg/kg) or HxCDD (1400 microg/kg). Females were given 1.5 times lower doses than males. The dosing period was 13 weeks, after which half of the rats were necropsied and the rest provided with an off-dose period of another 13 weeks. Liver concentrations as determined by GC-MS reflected the doses administered. Body weight gain was dose-dependently reduced throughout the study. Mortality rates at the end of the off-dose period were 80 and 60% for the two highest dosages (mixture) in males and 70 and 10% for females. Clinical signs and necropsy findings suggested that the cause of death was related to wasting, hemorrhage, and anemia. Prothrombin times were prolonged and platelet counts were decreased in some rats receiving high doses. This study provides in vivo support for the validity of the assumption of additive toxicity of CDDs as currently used in the toxicity equivalency factor approach to assess the toxicity of mixtures of CDDs.
将20只雄性和20只雌性大鼠分为几组,分别给予五种不同剂量的2,3,7,8-四氯二苯并-对-二噁英(TCDD)、1,2,3,7,8-五氯二苯并二噁英(PCDD)、1,2,3,4,7,8-六氯二苯并二噁英(HxCDD)和1,2,3,4,6,7,8-七氯二苯并二噁英(HpCDD)混合物。剂量是根据急性毒性数据和先前对HpCDD的亚慢性研究得出的相对效力因子来选择的。该混合物的构成方式是,每种同系物对总毒性当量的贡献均为四分之一。总剂量分为四个每日负荷剂量和六个每两周一次的维持剂量。雄性大鼠的最高总剂量为17.5微克/千克TCDD、87.5微克/千克PCDD、350微克/千克HxCDD和2500微克/千克HpCDD。阳性对照给予PCDD(350微克/千克)或HxCDD(1400微克/千克)。雌性大鼠的剂量比雄性低1.5倍。给药期为13周,之后对一半的大鼠进行尸检,其余大鼠给予另外13周的停药期。通过气相色谱-质谱法测定的肝脏浓度反映了所给予的剂量。在整个研究过程中,体重增加呈剂量依赖性降低。在停药期结束时,雄性大鼠中两种最高剂量(混合物)的死亡率分别为80%和60%,雌性大鼠的死亡率分别为70%和10%。临床症状和尸检结果表明,死亡原因与消瘦、出血和贫血有关。一些接受高剂量的大鼠凝血酶原时间延长,血小板计数减少。本研究为目前在毒性当量因子方法中用于评估二噁英混合物毒性的二噁英相加毒性假设的有效性提供了体内支持。